Passive immunotherapy using intravenous immunoglobulin at a dose of 400 mg/kg has shown beneficial effects in uncontrolled studies and is recommended in the guidelines, but there is no significant evidence for its use 9, 29, 35.
La inmunoterapia pasiva utilizando inmunoglobulina endovenosa a una dosis de 400 mg/kg ha mostrado efectos benéficos en estudios no controlados y es recomendada en las guías, aunque no existe evidencia significativa para su uso 9, 29, 35.